National Institutes of Health researchers reported new insights into why GLP-1 receptor agonists such as Ozempic and Wegovy eventually plateau in producing weight loss.
Appetite-regulating neurons showed changing responses over extended treatment periods, suggesting neural adaptation dampens drug effectiveness.
Clinicians observing patient outcomes have noted diminishing returns after initial rapid weight reduction on GLP-1 therapies.
Understanding adaptive mechanisms may guide combination strategies or dosing adjustments to sustain metabolic benefits.
The NIH emphasized that findings derive from controlled research and should inform, not replace, individualized medical supervision.
GLP-1 receptor agonists mimic incretin hormones that reduce appetite through central nervous system pathways involving hypothalamic neurons.
Patients and clinicians have reported weight loss plateaus after initial months of treatment with semaglutide-based medications marketed as Ozempic and Wegovy.
NIH investigators used neural recording methods to track changing activity patterns in appetite-regulating cell populations during extended drug exposure.
Endocrinology clinics report varied patient experiences with GLP-1 therapy duration before weight loss stabilizes or reverses modestly.
Pharmaceutical researchers are exploring whether dose escalation strategies or combination agents could overcome neural adaptation to GLP-1 drugs.
NIH-funded follow-up studies will examine whether adjusting GLP-1 dosing schedules can counter appetite neuron adaptation linked to weight loss plateaus.
New NIH research revealed why GLP-1 receptor agonists eventually stop working by showing that appetite-regulating neurons respond differently over time.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/